Company Overview and News


Add PRTA
to your dashboard

Headline News

Top Analyst Upgrades and Downgrades: Cardinal Health, Monster Beverage, PayPal, Viacom, Verizon, Wal-Mart and More

2017-11-20 247wallst
Futures are trading modestly higher this morning as we prepare to open up the holiday-shortened trading week. While today could be somewhat active, you can bet that many Wall Street traders are looking towards the door in anticipation of the Thanksgiving break and a long weekend. The one trend that has dominated this bull market is that investors keep finding new reasons to buy stocks after every single sell-off. (183-0)

Q3 Hedge Fund Letters – Cap Intro (Without The Fees) Galore [UPDATED] 

2017-11-10 archive.mlgngo
ValueWalk's daily newsletter below -welcome to the grand survey with prizes - check it out here Update profile - switch to our weekly newsletter here (34-0)

The 12 Valuation Ratios Every Investor Should Know 

2017-11-09 archive.mlgngo
ValueWalk's daily newsletter below -welcome to the grand survey with prizes - check it out here Update profile - switch to our weekly newsletter here (34-0)

PRESS DIGEST- British Business - Nov 9

2017-11-09 reuters
Nov 9 - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. (33-0)

Madera Technology Up 43% YTD On The Shocking Stat Of The Day 

2017-11-08 archive.mlgngo
ValueWalk's daily newsletter below -welcome to the grand survey with prizes - check it out here Update profile - switch to our weekly newsletter here (39-0)

Best Near-Term Price Gains Ahead For Biotechnology Developer Stocks

2016-11-14 seekingalpha
The presidential election brings new focus to many stock groups, especially those in the healthcare arena.

Best Near-Term Price Gains Ahead For: Biotechnology Developers Stocks

2016-11-14 seekingalpha
The presidential election brings new focus to many stock groups, especially those in the healthcare arena.

Premarket Biotech Digest: Seeking Alpha Biotech Idea, Gilead Sales Updates, Sanofi Diabetes Collaboration

2016-09-18 seekingalpha
This week onward, every Monday we will discuss a major article idea published on Seeking Alpha on healthcare.

Premarket Biotech Digest: Clovis A Buy, Cellceutix Rallies, Pfizer's Avelumab Milestone

2016-09-18 seekingalpha
(Announcing November Discounts. Only for the month of November, the first 11 (100-89) new subscribers will get a huge discount to my popular biotech service. Click this link to find out how much you can save).

Finding Value With The Piotroski F-Score Year 2: Part 1

2016-09-17 seekingalpha
This is the first article of the second series of articles looking at the investment performance of the Piotroski F-Score.

Premarket Biotech Digest: Geron On The Move, Repros Tumbles, GlobeImmune Rumors

2016-09-17 seekingalpha
(Announcing December Discounts. Only for the month of December, the first 100 new subscribers will get a huge discount to my popular biotech service. Click this link to find out how much you can save).

Biotech Forum Daily Digest: Biotech Tries To End Week On High Note. Lexicon Soaring On Trial Results. Spotlight On Prothena

2016-09-09 seekingalpha
The biotech sector has outperformed the overall market so far throughout the week, although the area is weak, like other equities, early this Friday.

Prothena Builds Case For Amyloidosis Valuation

2016-08-30 seekingalpha
Prothena (NASDAQ:PRTA) is heading towards a big moment perhaps as early as next year, when pivotal data for amyloidosis treatment NEOD001 are due to emerge. Sellside analysts are suggesting near-blockbuster figures for the drug by 2022.

The Stakes Rise For Unpartnered Assets

2016-08-12 seekingalpha
As the possibility of raising substantial amounts of cash in the equity markets dims for all but those with astonishingly good news, deal making is becoming ever more important. A look at those reckoned by the sellside to have the most valuable unpartnered projects reveals that CNS assets appear to be dominant (see table below).

Why Prothena Corp plc Skyrocketed 43% in July

2016-08-07 fool
What: Ahead of second-quarter financial results and key trial data for its Parkinson's disease drug, shares in Prothena Corp. plc (NASDAQ:PRTA) soared 43.2% in July, according to S&P Global Market Intelligence.

CUSIP: G72800108